Antibiotics have saved millions of lives in the past seven decades, but their future usefulness is now severely threatened by the spread of resistance genes and the shortage of new substances that can overcome resistance (Curr. Biol. (2013) 23, R1063-R1065). Several recent reports, including one from the WHO released in April, have confirmed that this problem is now on the verge of turning into a humanitarian disaster on a global scale.
Due to the imminent danger, the search for alternatives to traditional antibiotics has become an urgent priority. One promising avenue is the use of natural bacteriophages in mixtures known as phage cocktails. Originally proposed by the discoverer of phages, Felix d'Herelle, the idea was pursued in the Soviet Union (especially in Tbilisi, Georgia) and Poland, but largely ignored in the Western world, as antibiotics were considered superior (Curr. Biol. (2011) 21, R267-R270) . Now, however, researchers in Germany, France, and Belgium, among other countries, are busy identifying phages for therapeutic human uses. The Food and Drugs Administration (FDA) in the US has already approved the use of phages in the treatment of food products, specifically raw meat. Trials of phages as biopesticides in agriculture have also been reported for a number of crops, including tomato, potato, citrus fruit and onion.
If phages are going to replace all or some of the current applications of antibiotics spanning not only medicine but also agriculture and aquaculture, will we just repeat the mistake we made with antibiotics and breed phageresistant strains? The outcome is more difficult to predict than in the case of antibiotics, as the phages co-evolve with their host bacteria as well as the eukaryotic host infected by those bacteria, so there is an ecological triangle that needs to be understood.
Ecological triangulation
Much of the recent research on the ecology of phages infecting disease-causing bacteria has been done on plants. Therefore, the use of phages to treat plant disease is already becoming a very real option. At a recent one-day, NERC-funded symposium hosted by the group of Rob Jackson at the University of Reading, botanists and ecologists from several institutions pondered the possibility of phage therapy for trees.
Britt Koskella from the University of Exeter discussed the issue on the basis of research carried out with her PhD student Sean Meaden into the co-evolution of phages with their hosts.
On a very practical level, Koskella addressed the question of how to select phages for applications and how to assess their specificity. "Based on what we know from our tree research, phages are out there already and they are well-adapted to their local bacteria including those pathogens causing important tree diseases. Therefore, in designing treatments it makes good sense to first look at which phages are successful in nature and why," Koskella said.
As far as tests for specificity are concerned, traditional laboratory assays based on a small selection of cultured strains may not be sufficient to rule out unexpected side effects. Instead, Koskella argued, the tests
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should be based on the diversity of species that the phages are likely to encounter in the field.
Phages are typically applied as a cocktail of several variants, both in order to cover different strains of the target species and to make it less likely that they evolve resistance, as they often do in the wild. Should resistance be observed, however, this does not automatically mean the failure of the treatment. As resistance to specific kinds of phages can come at a relatively high fitness cost to the host, bacteria will only keep the resistance traits that are useful in an acute threat situation. Switching the phage treatment on a bacterial population can therefore overcome its resistance.
"We are now looking into the possibility of creating unique combinations of phages that force the bacteria to evolve particularly costly resistance. This means that resistance is more likely to be lost once the treatment has stopped, and is less likely to spread to other hosts," Koskella said.
This kind of response may also help to avoid a repetition of the antibiotics crisis in phages. As Meaden and Koskella have explained in a recent review (Frontiers in Microbiology (2013) 4, 358), a rapid response in switching regimes will help to keep resistance at bay. For this to be practically feasible in medical applications of phages, protocols have to be found for the production of phage cocktails that are considered safe in human application, such that new cocktails can be introduced without the delay of new medical trials.
Beyond the resistance problem, which is broadly analogous to the one we already have with antibiotics, there are a few additional problems and questions arising from the specific properties of phages and their ability to propagate and evolve. For one, the fact that the production of phages generally requires the use of their bacterial host, a phage therapy for a highly dangerous bacterium might have to be produced in high-security laboratories with all the difficulties attached to this.
Furthermore, as Meaden and Koskella explain in their review, the presence of phages tends to facilitate horizontal gene transfer between bacteria, which in turn may further the spread of undesirable genetic traits including virulence traits and resistance to antibiotics. To avoid exaggerated fears, however, it is important to make the distinction between lytic and temperate phages. Lytic phages can only propagate by killing their hosts, and they are the kind that one would consider using as antimicrobial agents. Temperate phages can lead a more peaceful coexistence with their hosts and sometimes carry virulence factors that make their hosts more dangerous, the most prominent example being the cholera toxin. These would obviously not be considered for phage therapy.
Further phage-specific ecological complications that Koskella and Meaden have highlighted in their review include the impact that phages can have on natural ecosystems, including, in medical applications, the gut microbiome, as well as the intrinsic unpredictability of the doses of phages that will be present after they are released. This type of ecological question, Koskella emphasizes, is easier to address in tree hosts than in human patients, but the results should be broadly applicable.
Nevertheless, the authors conclude that, with improving ecological understanding and with the modern analytical tools allowing the monitoring of phage populations after their release, the application of phages in the environment and in medical practice can be handled responsibly and may provide a solution for the current antibiotics crisis.
Treating tree disease
The laboratory of Rob Jackson at Reading, which hosted the recent meeting on phage therapy for trees, started a collaborative study into the possibility of using phages to treat bleeding canker disease in horse chestnut trees in 2010, together with Michael Brockhurst at York and the company Bartletts Tree Experts. The research, mostly conducted by Sarah James at Reading in the course of her PhD thesis, identified a number of phage strains that can infect the bleeding canker pathogen Pseudomonas syringae pv. aesculi.
Horse chestnut mainly serves for decorative purposes in parks in the UK and has no major economic importance, but, given the ecological research conducted by Koskella and others on this system, it offers a well-defined model for phage therapy in trees. In contrast to the earlier work from Koskella and other ecologists, Jackson's team not only observed and used natural phages, but also manipulated the phage strains in the laboratory, breeding them to optimise their ability to infect the plant pathogen.
The researchers are aiming to blend some of these derived, more infectious strains together with the wild type found in the natural environment, in order to kill off the pathogens more effectively. Having optimised their phage cocktails, the researchers have now reached the stage of early application trials, attempting to cure infected trees.
"Tantalisingly, our preliminary tests show promise as the application of a two-phage cocktail helped to reduce disease symptoms and pathogen numbers in infection sites in the trunk of horse chestnut saplings. However, this needs to be repeated in more trees of different size and ages," Jackson explains. "Moreover, another critical question emerges -does the co-evolution (breeding) seen in vitro occur in the plant and can it occur with phage cocktails? This needs to be addressed to determine if, over time, phage use would become redundant much the same as the use of some antibiotics."
To rule out such unwanted results, Jackson says, phage strains intended for applications -even if used in cocktails -must be tested individually for their evolutionary dynamic in the ecological context. "We must also examine the molecular changes occurring to determine if there is any likely end-point in bacterial resistance -will, using enough phages in a cocktail, bacteria be prevented from evolving resistance? This helps with risk assessment -to predict the likelihood of resistance emerging," Jackson concludes.
Meanwhile, a different strain of the bleeding canker bacterium, Pseudomonas syringae pv. actinidiae, is devastating kiwi plantations in New Zealand, threatening to cause significant economic damage to the country. One of the urgent problems connected to the rapid spread of antibiotics resistance is the occurrence in hospitals of multidrug resistant Staphylococcus aureus, widely known as MRSA -or "hospital superbug" in the popular media. The group of Robert Lavigne at the University of Leuven, Belgium, has recently identified a pair of new phage strains dubbed Romulus and Remus, which represent a new species within the known genus of Twortlikevirus (J. Virol. (2013), 87, 3237-3247) . Detailed molecular analysis of how these phages interact with their hosts suggests that they might be suitable for phage therapy of MRSA infections, as they can dissolve biofilms, which are a particularly tricky problem in the application of antibiotics in infections.
Iyo Takemura-Uchiyama and colleagues at Kochi University, Japan, have also described new phages active against MRSA (FEMS Microbiol. Lett. (2013) 347, 52-60) . They tested its therapeutic efficiency in a new setup using silkworm larvae, which they advocate as a cost-efficient way of replacing animal tests with rodents (Nature (2014) 509, S9).
The company Novolytics, based in Chorley, Lancashire, UK, is also in the process of developing phage therapies against MRSA. At the Reading meeting, John Hardcastle from the company discussed the commercial and regulatory challenges attached to such endeavours.
Christine Rohde and Johannes Wittmann at the German Collection of Microorganisms and Cell Cultures in Braunschweig are in the process of expanding their arsenal of medically useful phage strains. Most recently, they reported the characterisation of phages against the opportunistic bacterial pathogen Achromobacter xylosoxidans, which causes complications in patients with cystic fibrosis and often carries multiple antibiotic resistance traits (PLoS One (2014) 9, e86935; Virology Journal (2014) 11, 14) .
While research aimed at medical application of phages is making rapid progress, a key problem remains the mismatch between the biological properties of phages and the established regulatory frameworks for drugs and medical procedures. As mentioned above, the success of phage therapy may depend on rapid change to the recipe, outrunning the evolution of the targeted bacteria. This need for change and for efficient use of the natural diversity of phages runs against the grain of the established drug regulations and guidelines which aim to pin down the precise and unchangeable composition of a given treatment and require timeintensive testing of this very specific product.
Therefore, Gilbert Verbeken and colleagues at Leuven and Brussels have argued that adaptation of existing drug rules for phages would be impractical (Arch. Immunol. Ther. Exp. (2014) 62, 117-129) . The authors call on the European Union to set up new guidelines specifically for phage therapy, based on the ecological knowledge accumulated in recent years. The important message to regulators as well as to future users of phage therapies is that, even though they may one day replace antibiotics, they don't behave like antibiotics, and we, as a civilisation, definitely don't want to repeat the mistakes we made with antibiotics.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk recycling nutrients that previously were entrapped in the sedimentary column, deeper burrowing may have been crucial to igniting the evolutionary 'explosion' in the Cambrian during which a host of new body plans appeared; and it was surprising just how quickly thereafter a wide range of foraging and grazing habits were innovated on the Phanerozoic seafloor.
Seilacher recognised that it is not absolutely necessary to know exactly what kind of organism was at work on a track or trail to understand the exploitation of the seafloor. Which animal left a trace is often impossible to determine, as body fossils are rarely preserved in the same paleoenvironments as trace fossils. However, the bigger picture of environmental exploitation was accessible to analysis, as analogous foraging techniques had evolved repeatedly through geological time. Seilacher was incomparable when it came to 'reading' traces as biological activity. But he was equally convinced that some very particular 'species' of ichnofossils could be used to date rocks in areas where body fossils were lacking. This was applied with success to correlate Palaeozoic rocks over huge areas of North Africa that had previously defied geological classification. Although much of his groundwork on ichnology was done in the twentieth century, Seilacher finally summarised his lifetime's interest in the book Trace Fossil Analysis published in 2007 when he was over eighty.
It was a logical extension of his ichnological work -and also a long-standing interest in special fossil preservations, which he termed Konservat Lagerstätten in 1970 -that propelled Seilacher to study the curious Precambrian fossils of the Ediacaran rocks of South Australia and elsewhere. These large -and largely mysterious -organisms were the only substantial metazoans preceding the Cambrian appearance of our familiar animal phyla, and they are preserved in the kind of sandstones and shales with which Seilacher was so familiar. They comprise a very wide range of morphologies, and some had previously been interpreted in relation to younger metazoans, as 'missing links.' Characteristically, Seilacher at once came back with a radically dissenting interpretation: these were quilted organisms of a kind radically different from subsequent metazoans,
Dolf Seilacher (1925-2014) Richard Fortey
For decades the tall and commanding presence of Dolf Seilacher at paleontology conferences was something that was both welcomed and dreaded by younger colleagues: welcomed because it was flattering having the invariably rapt attention of one of the few globally recognised scientists in the field; dreaded because that attention often transmuted into a penetrating question coming from a direction nobody could have anticipated. Seilacher was one of the great lateral thinkers. He belonged neither to the earth nor to the life sciences, but made fundamental, synergistic contributions to both. This was finally recognised by the award of the Crafoord Prize in 1992.
Most paleontologists study fossils in the privacy of their own laboratories. The ideal fossil might be cleaned of its sedimentary matrix the better to get down to the details. Dolf Seilacher was as interested in the relationships of fossils to the enclosing rock as he was in any bone or shell. During the 1960s and 1970s he was seminal in the development of the study of the tracks and trails left by biological activity on the surface or within sedimentsthose destined to become trace fossils, or 'ichnofossils' as they are known. He discriminated various ways in which such tracks could be impressed upon or cast by clays and sands, so that a previous, rather naïve view based essentially on the image of a footfall upon a beach became much more nuanced. Even the most delicate and momentary behavioural maneuvers within the sediment could leave an eternal imprint if the conditions for their preservation were just right. Recognition of different types of locomotion and foraging activities then became integrated with geological field studies around the world that proved that there were distinct suites of ichnofossils typifying different ancient marine depth-zones and habitats. The broad evolutionary sweep of trophic history thus became a subject for rational observation: for example, by
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